Last reviewed · How we verify
FVIII products
FVIII products is a Coagulation factor VIII replacement therapy Small molecule drug developed by Bayer. It is currently in Phase 2 development for Hemophilia A, Hemophilia A with inhibitors.
FVIII products replace or supplement the missing or defective clotting factor VIII in the blood to help the blood to clot normally.
Bayer's FVIII products are advancing through various clinical trials, including gene therapy and novel replacement therapies for severe hemophilia A. These efforts aim to improve safety, efficacy, and patient outcomes, positioning Bayer as a leader in hemophilia treatment.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Bayer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FVIII products |
|---|---|
| Sponsor | Bayer |
| Drug class | Coagulation factor VIII replacement therapy |
| Target | Factor VIII |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
FVIII products work by providing the necessary clotting factor VIII to help the blood to form a clot. This is particularly important for individuals with hemophilia A, a genetic disorder characterized by the deficiency of this clotting factor. By replacing or supplementing the missing or defective FVIII, these products help to prevent or control bleeding episodes.
Approved indications
- Hemophilia A
- Hemophilia A with inhibitors
Common side effects
- Headache
- Pain
- Nausea
- Fatigue
- Injection site reaction
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FVIII products CI brief — competitive landscape report
- FVIII products updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about FVIII products
What is FVIII products?
How does FVIII products work?
What is FVIII products used for?
Who makes FVIII products?
What drug class is FVIII products in?
What development phase is FVIII products in?
What are the side effects of FVIII products?
What does FVIII products target?
Related
- Drug class: All Coagulation factor VIII replacement therapy drugs
- Target: All drugs targeting Factor VIII
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Hemophilia A
- Indication: Drugs for Hemophilia A with inhibitors
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing